A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Inclusion Criteria

• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• •Must have recovered from all side effects of their most recent systemic or local treatment
• •Adequate hematological, renal and liver function
• •For solid tumors only:
• •Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation and that are resistant to standard therapy or for which standard or curative therapy does not exist
• •Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)
• •For multiple myeloma only:
• •Confirmed diagnosis of multiple myeloma with a BRAF V600 mutation
• •Must have received at least one prior systemic therapy for the treatment of multiple myeloma
• •Treated with local radiotherapy
• •Must have relapsed and/or refractory multiple myeloma with measurable disease